How many insider trades does FilingIQ track for MNPR?

FilingIQ tracks 277 Form 4 insider transactions for MNPR (Monopar Therapeutics), covering filings from Dec 20, 2019 onwards. 40 of those are dated within the last 90 days.

Are MNPR insiders net buyers or net sellers?

Across the full Form 4 history for MNPR, 19 transactions (7%) were open-market purchases and 38 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MNPR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is MNPR in?

Monopar Therapeutics (MNPR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $370.82M.

MNPR insider trading

NasdaqCM Healthcare

Monopar Therapeutics: insider trade history from SEC Form 4 filings.

Total Form 4 trades

277

Last 90 days

Buys / sells

7% / 14%

Market cap

$370.82M

About Monopar Therapeutics

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Company website: www.monopartx.com

MNPR insider activity at a glance

FilingIQ tracks 277 insider transactions for MNPR in filings since Dec 20, 2019. The most recent transaction is dated Oct 1, 2026.

Across the full history, 19 open-market purchases and 38 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MNPR insider trades is 68.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MNPR trades on FilingIQ Raw filings on SEC EDGAR

Latest MNPR Form 4 filings

STARR CHRISTOPHER M

SM Oct 5, 2026

Cittadine Andrew Chief Operating Officer

FM Oct 2, 2026

Robinson Chandler Chief Executive Officer

FM Oct 2, 2026

Vu Quan Anh Chief Financial Officer

FM Oct 2, 2026

Robinson Chandler Chief Executive Officer

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Top insiders trading MNPR

Robinson Chandler

38 trades · score 75.0

Cittadine Andrew

34 trades · score 72.8

Frequently asked

How many insider trades does FilingIQ track for MNPR?: FilingIQ tracks 277 Form 4 insider transactions for MNPR (Monopar Therapeutics), covering filings from Dec 20, 2019 onwards. 40 of those are dated within the last 90 days.
Are MNPR insiders net buyers or net sellers?: Across the full Form 4 history for MNPR, 19 transactions (7%) were open-market purchases and 38 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MNPR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is MNPR in?: Monopar Therapeutics (MNPR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $370.82M.

Methodology & sources

Every MNPR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.